Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, according to the company.
The revolving credit facility continues to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions. This supports Knight's ongoing growth strategy across its pan-American pharmaceutical business. The repayment underscores the company's financial discipline and ability to generate sufficient cash to reduce debt quickly.
Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. The company's shares trade on the TSX under the symbol GUD.
For more information about the company, please visit www.knighttx.com. The full press release can be viewed at https://ibn.fm/8eluB.
The repayment is a positive signal to investors, indicating that the Paladin acquisition is generating expected returns and that Knight can manage its leverage effectively. This financial move may also position the company for future acquisitions or investments, given the remaining borrowing capacity and accordion feature. As Knight continues to expand its pharmaceutical portfolio across the Americas, strong cash flow and a healthy balance sheet will be critical to executing its growth strategy.
